Inactive Instrument

Celltrion, Inc. Stock Korea S.E.

Equities

068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E.
- KRW - Intraday chart for Celltrion, Inc.
Sales 2024 * 3,447B 2.51B Sales 2025 * 4,254B 3.09B Capitalization 38,854B 28.25B
Net income 2024 * 536B 390M Net income 2025 * 1,234B 897M EV / Sales 2024 * 11.5 x
Net Debt 2024 * 891B 648M Net Debt 2025 * 82.29B 59.83M EV / Sales 2025 * 9.15 x
P/E ratio 2024 *
75.1 x
P/E ratio 2025 *
32.7 x
Employees -
Yield 2024 *
0.25%
Yield 2025 *
0.26%
Free-Float 66.89%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 62 07-04-23
Director of Finance/CFO 49 -
Chairman 66 -
Members of the board TitleAgeSince
Chairman 66 -
Director/Board Member 66 -
Director/Board Member 65 08-07-16
More insiders
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
More about the company